Descripción de negocio
Spexis AG is a research-driven clinical-stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance leveraging the company's leading macrocyclic peptide technology platform. Spexis AG is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer and exploring its potential in other cancer indications. In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. The company's lead OMPTA program is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Spexis AG is based in Allschwil near Basel and is listed on the SIX Swiss Exchange.
Consejo de gestión & Consejo de supervisión
| CEO |
| Jeffrey D. Wager |
| Consejo de gestión |
| Hernan Levett, Stephan Wehselau, Juergen Froehlich |
| Consejo de supervisión |
| Jeffrey D. Wager, Dennis Ausiello, Bernard Bollag, Dr. Kuno Sommer, Robert Clarke , Dan Hartman |
Datos de la empresa
| Nombre: |
Spexis AG |
| Dirección: |
Hegenheimermattweg 125,CH-4123 Allschwil |
| Teléfono: |
+41-61-567-1600 |
| Fax: |
- |
| E-mail: |
info@polyphor.com
|
| Internet: |
https://www.polyphor.com/ |
| Industria: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Subsector: |
Pharmaceuticals |
| Fin del año financiero: |
31/12 |
| Acciones de libre circulación: |
- |
| Fecha de OPI: |
15/05/2018 |
Relación con inversores
| Nombre: |
Hernan Levett |
| IR teléfono: |
+41-61-567-1624 |
| IR-fax: |
- |
| IR e-mail: |
IR@spexisbio.com
|
